HEALTH

GSK awards $200,000 in grants to nonprofit healthcare organizations reaching underserved communities

BY Michael Johnsen

RESEARCH TRIANGLE PARK, N.C. — GlaxoSmithKline on Thursday announced the five recipients of its annual GlaxoSmithKline IMPACT Awards. In total, the North Carolina and Philadelphia-area healthcare nonprofit organizations will receive $200,000 in grant funding ($40,000 each) for providing access to healthcare for the underserved in their communities.

"The GlaxoSmithKline IMPACT Award winners are helping to make their communities stronger and healthier," stated Mary Linda Andrews, director of community partnerships, GSK. "The dedicated teams of professionals and volunteers at these organizations are working in innovative ways to provide access to healthcare at a time when people need it most."

The following organizations will receive their awards at a ceremony on Dec. 11 in Research Triangle Park:

  • Piedmont Health Services and Sickle Cell Agency, Greensboro, N.C.
  • Restoration Place Ministries, Greensboro, N.C.
  • The Servant Center, Greensboro, N.C.
  • Triad Health Project, Greensboro, N.C.
  • Institute for Safe Families, Philadelphia

In North Carolina, GSK works in partnership with Durham-based Triangle Community Foundation, a grant-making organization that connects resources with needs through community-based philanthropy.

"Millions of Americans fall between the gaps and are not receiving the most basic healthcare services," stated Lori O’Keefe, COO at TCF. "Our partnership with GSK celebrates and supports groups that are filling those gaps and creating hope for thousands of members of our communities."

The GlaxoSmithKline IMPACT Awards — which stands for Innovation, Management, Partnership, Achievement, Community focus and Targeting needs of diverse and underserved populations — honor nonprofit organizations that have a significant impact on their communities and are capable, proactive and effective in their work.

To qualify for a GlaxoSmithKline IMPACT award, organizations must be located in the eligible counties and have a primary mission to provide access to community healthcare services. Each applicant must have annual total operating expenses between $160,000 and $3 million, and have been in existence as a 501(c)(3) nonprofit organization for at least five years.

All organizations are recognized for the success and achievements of their existing overall body of work, not just for new or specific initiatives. A panel of healthcare delivery experts and GlaxoSmithKline representatives determine the winners based on a strong demonstration of ongoing success in providing access to healthcare, commitment to serving people in need, facilitation of healthcare delivery, creative partnerships and policy development, and a solid record of achievement, management and leadership. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
HEALTH

C&D to initiate trial of its Trojan Vibrations line across several urban markets

BY Michael Johnsen

PRINCETON, N.J. — Church & Dwight will be initiating trial of its Trojan Vibrations personal massagers with a multi-city giveaway, the company announced Wednesday. Beginning in Washington on Nov. 13, Church & Dwight will feature its latest product innovations via a specially-designed Trojan Vibrations Pleasure Carts that are modeled after traditional hot dog carts.

"With the success of the Trojan vibrator giveaway in New York City, it is evident that Americans understand that pleasure is a normal part of sexually healthy lives," stated Bruce Weiss, VP marketing, Trojan sexual health. "By innovating high-quality vibrators and making them easily accessible on drug store, mass merchandiser and grocery store shelves, Trojan remains dedicated to taking pleasure out of the bedroom and into the mainstream."

People can track the tour and uncover upcoming stops by visiting Facebook.com/TrojanVibrations.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
HEALTH

Acura Pharmaceuticals moves forward with plans to launch diversion-hindering PSE product

BY Michael Johnsen

PALATINE, Ill. — Acura Pharmaceuticals on Wednesday shared with analysts details on its launch strategy of Nexafed, a pseudoephedrine formulated such that it inhibits the diversion to methamphetamnine. 

We have begun executing a plan to generate awareness of Nexafed with pharmacists to support stocking of Nexafed in the pharmacies and generate consumer recommendations by the pharmacists," Acura president and CEO Bob Jones told analysts Wednesday morning. "We have met numerous independent pharmacists from several states at recent trade shows, and have found an enthusiastic level of interest in Nexafed. These pharmacists appear pleased that we intend to offer Nexafed at a price comparable to similar branded products."

Nexafed will still fall under sales restriction dictated by the Combat Methamphetamine Epidemic Act of 2006, which requires all pseudoephedrine products to be placed behind the pharmacy counter, Jones noted, as well as more stringent state restrictions where applicable. Both Oregon and Mississippi require a prescription for any PSE-containing products, for example. 

"Our long-term objective is really twofold. One is to continue to improve upon our technology, which we believe we can do," Jones said. The second long-term objective would be to demonstrate real, practical experience in the marketplace relative to disrupting meth production, Jones added. Following that, Acura would then be to make applications either to individual states or to the Drug Enforcement Agency in an effort to get exemptions from relative sales restrictions.  

"We look at the independent pharmacies as being the early adopters," Jones said. "We think if we establish the product with independent pharmacists, that will demonstrate to the chains [the benefits of Nexafed]."

According to the company, Nexafed will be the first marketed product utilizing Acura’s proprietary Impede technology, and expects to make its first shipments in December.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?